Evidence map›Paper›PMID 39060836›Full record

ReviewHeart failure reviews2024

Stress echocardiography in heart failure patients: additive value and caveats.

Maria Concetta Pastore, Alessandro Campora, Giulia Elena Mandoli, Matteo Lisi, Giovanni Benfari, Federica Ilardi, Alessandro Malagoli, Simona Sperlongano, Michael Y Henein, Matteo Cameli and 2 more

Abstract readReview
In one paragraph

Review in Heart failure reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Ginsenoside RbPharmaceuticals (Basel, Switzerland) · 2025
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maria Concetta PastoreDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci1 , Siena, Italy. pastore2411@gmail.com.ORCID http://orcid.org/0000-0002-7223-141X
Alessandro CamporaDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci1 , Siena, Italy.
Giulia Elena MandoliDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci1 , Siena, Italy.
Matteo LisiDepartment of Cardiovascular Disease - AUSL Romagna, Division of Cardiology, Ospedale S. Maria Delle Croci, Viale Randi 5, 48121, Ravenna, Italy.
Giovanni BenfariSection of Cardiology, Department of Medicine, University of Verona, Verona, Italy.
Federica IlardiDepartment of Advanced Biomedical Sciences, Division of Cardiology, Federico II University Hospital, Via S. Pansini 5, 80131, Naples, Italy.
Alessandro MalagoliDivision of Cardiology, Nephro-Cardiovascular Department, Baggiovara Hospital, Modena, Italy.
Simona SperlonganoDivision of Cardiology, Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli, Naples, Italy.
Michael Y HeneinDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Matteo CameliDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci1 , Siena, Italy.
Antonello D'AndreaDepartment of Cardiology, Umberto I Hospital, 84014, Nocera Inferiore, SA, Italy.
Echocardiography Working Group of the Italian Society of Cardiology (SIC)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a clinical syndrome characterized by well-defined signs and symptoms due to structural and/or myocardial functional impairment, resulting in raised intracardiac pressures and/or inadequate cardiac stroke volume at rest or during exercise. This could derive from direct ischemic myocardial injury or other chronic pathological conditions, including valvular heart disease (VHD) and primary myocardial disease. Early identification of HF etiology is essential for accurate diagnosis and initiation of early and appropriate treatment. Thus, the presence of accurate means for early diagnosis of HF symptoms or subclinical phases is fundamental, among which echocardiography being the first line diagnostic investigation. Echocardiography could be performed at rest, to identify overt structural and functional abnormalities or during physical or pharmacological stress, in order to elicit subclinical myocardial function impairment e.g. wall motion abnormalities and raised ventricular filling pressures. Beyond diagnosis of ischemic heart disease, stress echocardiography (SE) has recently shown its unique value for the evaluation of diastolic heart failure, VHD, non-ischemic cardiomyopathies and pulmonary hypertension, with recommendations from international societies in several clinical settings. All these features make SE an important additional tool, not only for diagnostic assessment, but also for prognostic stratification and therapeutic management of patients with HF. In this review, the unique value of SE in the evaluation of HF patients will be described, with the objective to provide an overview of the validated methods for each setting, particularly for HF management.

Indexed as

Echocardiography, StressHeart FailureHumansPrognosisStroke VolumeDiagnosisExerciseHeart failureStress echocardiographyValvular heart disease

Identifiers

PMID39060836
PMCPMC11306652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.